Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Desloratadine. Nabilone may increase the central nervous system depressant (CNS depressant) activities of Desloratadine. The risk or severity of adverse effects can be increased when Bupivacaine is combined with Desloratadine. The risk or severity of adverse effects can be increased when Ethosuximide is combined with Desloratadine. The risk or severity of adverse effects can be increased when Desloratadine is combined with Solifenacin. The risk or severity of adverse effects can be increased when Oxazepam is combined with Desloratadine. The risk or severity of adverse effects can be increased when Aceprometazine is combined with Desloratadine. The risk or severity of adverse effects can be increased when Gepirone is combined with Desloratadine. The risk or severity of adverse effects can be increased when Lidocaine is combined with Desloratadine. The risk or severity of adverse effects can be increased when Nalbuphine is combined with Desloratadine. The risk or severity of adverse effects can be increased when Butabarbital is combined with Desloratadine. The serum concentration of Cilostazol can be increased when it is combined with Desloratadine. The risk or severity of adverse effects can be increased when Desloratadine is combined with Methylscopolamine bromide. The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Desloratadine. The risk or severity of adverse effects can be increased when Etifoxine is combined with Desloratadine. The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Desloratadine. The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Desloratadine. The risk or severity of adverse effects can be increased when Entacapone is combined with Desloratadine. The risk or severity of adverse effects can be increased when Desloratadine is combined with Butylscopolamine. The risk or severity of adverse effects can be increased when Desloratadine is combined with Alaproclate. The risk or severity of adverse effects can be increased when Scopolamine is combined with Desloratadine. 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Desloratadine. The risk or severity of adverse effects can be increased when Desloratadine is combined with Oxitropium. The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Desloratadine. The serum concentration of Bendroflumethiazide can be increased when it is combined with Desloratadine. Desloratadine may increase the constipating activities of Ramosetron. The risk or severity of adverse effects can be increased when Clonidine is combined with Desloratadine. Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Desloratadine. The risk or severity of adverse effects can be increased when Propoxycaine is combined with Desloratadine. The therapeutic efficacy of Desloratadine can be decreased when used in combination with Demecarium. Chlorphentermine may decrease the sedative activities of Desloratadine. The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Desloratadine. The risk or severity of adverse effects can be increased when Tandospirone is combined with Desloratadine. The therapeutic efficacy of Desloratadine can be decreased when used in combination with Malathion. Desloratadine may increase the anticholinergic activities of Aclidinium. The risk or severity of adverse effects can be increased when Gabapentin is combined with Desloratadine. The serum concentration of Afatinib can be increased when it is combined with Desloratadine. The therapeutic efficacy of Desloratadine can be decreased when used in combination with Mefloquine. The risk or severity of adverse effects can be increased when Ritanserin is combined with Desloratadine. The risk or severity of adverse effects can be increased when Maprotiline is combined with Desloratadine. The risk or severity of adverse effects can be increased when Brompheniramine is combined with Desloratadine. The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Desloratadine. The risk or severity of adverse effects can be increased when Pipamperone is combined with Desloratadine. Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Desloratadine. Desloratadine may increase the ulcerogenic activities of Potassium Chloride. Mianserin may increase the anticholinergic activities of Desloratadine. The risk or severity of adverse effects can be increased when Procaine is combined with Desloratadine. Desloratadine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. The serum concentration of Metoprolol can be increased when it is combined with Desloratadine. The risk or severity of adverse effects can be increased when Desloratadine is combined with Difenoxin. The therapeutic efficacy of Desloratadine can be decreased when used in combination with Echothiophate. The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Desloratadine. The serum concentration of Silodosin can be increased when it is combined with Desloratadine. The risk or severity of adverse effects can be increased when Desloratadine is combined with Paroxetine. The risk or severity of adverse effects can be increased when Triazolam is combined with Desloratadine. The risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Desloratadine. Lisdexamfetamine may decrease the sedative activities of Desloratadine. Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Desloratadine. The risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Desloratadine. The risk or severity of adverse effects can be increased when Prazepam is combined with Desloratadine. The risk or severity of adverse effects can be increased when Ethyl chloride is combined with Desloratadine. The risk or severity of adverse effects can be increased when Imipramine is combined with Desloratadine. The risk or severity of adverse effects can be increased when Etomidate is combined with Desloratadine. The risk or severity of adverse effects can be increased when Methocarbamol is combined with Desloratadine. The risk or severity of adverse effects can be increased when Biperiden is combined with Desloratadine. The serum concentration of Ranolazine can be increased when it is combined with Desloratadine. The risk or severity of adverse effects can be increased when Felbamate is combined with Desloratadine. The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Desloratadine. The risk or severity of adverse effects can be increased when Trospium is combined with Desloratadine. The risk or severity of adverse effects can be increased when Trimipramine is combined with Desloratadine. The risk or severity of adverse effects can be increased when Meclizine is combined with Desloratadine. Methamphetamine may decrease the sedative activities of Desloratadine. The risk or severity of adverse effects can be increased when Norflurane is combined with Desloratadine. The risk or severity of adverse effects can be increased when Desloratadine is combined with Tasimelteon. The risk or severity of adverse effects can be increased when Chlormezanone is combined with Desloratadine. The risk or severity of adverse effects can be increased when Sufentanil is combined with Desloratadine. The serum concentration of Brentuximab vedotin can be increased when it is combined with Desloratadine. The risk or severity of adverse effects can be increased when Pramocaine is combined with Desloratadine. The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Desloratadine. The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Desloratadine. The risk or severity of adverse effects can be increased when Zaleplon is combined with Desloratadine. The risk or severity of adverse effects can be increased when Quazepam is combined with Desloratadine. The risk or severity of adverse effects can be increased when Proparacaine is combined with Desloratadine. The risk or severity of adverse effects can be increased when Desloratadine is combined with Nefazodone. Desloratadine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Midomafetamine may decrease the sedative activities of Desloratadine. The risk or severity of adverse effects can be increased when Ecopipam is combined with Desloratadine. The risk or severity of adverse effects can be increased when Alfaxalone is combined with Desloratadine. Diethylpropion may decrease the sedative activities of Desloratadine. The therapeutic efficacy of Desloratadine can be decreased when used in combination with Physostigmine. The risk or severity of adverse effects can be increased when Desloratadine is combined with Ramelteon. The risk or severity of adverse effects can be increased when Clemastine is combined with Desloratadine. Benzphetamine may decrease the sedative activities of Desloratadine. The risk or severity of adverse effects can be increased when Benzatropine is combined with Desloratadine. The risk or severity of adverse effects can be increased when DPDPE is combined with Desloratadine. Desloratadine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. The therapeutic efficacy of Desloratadine can be decreased when used in combination with Ginkgo biloba. The risk or severity of adverse effects can be increased when Desloratadine is combined with Gabapentin Enacarbil. The risk or severity of adverse effects can be increased when Loratadine is combined with Desloratadine. The risk or severity of adverse effects can be increased when Bromazepam is combined with Desloratadine. The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Desloratadine. The serum concentration of Ledipasvir can be increased when it is combined with Desloratadine. The risk or severity of adverse effects can be increased when Desloratadine is combined with Methsuximide. Amphetamine may decrease the sedative activities of Desloratadine. The risk or severity of adverse effects can be increased when Ethotoin is combined with Desloratadine. The risk or severity of adverse effects can be increased when Flurazepam is combined with Desloratadine. The risk or severity of adverse effects can be increased when Carbamazepine is combined with Desloratadine. Desloratadine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. The risk or severity of adverse effects can be increased when Meprobamate is combined with Desloratadine. The risk or severity of adverse effects can be increased when Clozapine is combined with Desloratadine. The risk or severity of adverse effects can be increased when Thiothixene is combined with Desloratadine. The risk or severity of adverse effects can be increased when Dextromoramide is combined with Desloratadine. The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Desloratadine. The risk or severity of adverse effects can be increased when Flupentixol is combined with Desloratadine. The therapeutic efficacy of Desloratadine can be decreased when used in combination with Memantine. The risk or severity of adverse effects can be increased when Dapiprazole is combined with Desloratadine. The risk or severity of adverse effects can be increased when Tetracaine is combined with Desloratadine. The risk or severity of adverse effects can be increased when Desloratadine is combined with Pomalidomide. The risk or severity of adverse effects can be increased when Desloratadine is combined with Indalpine. The risk or severity of adverse effects can be increased when Desloratadine is combined with Chlorphenoxamine. The serum concentration of Polythiazide can be increased when it is combined with Desloratadine. The therapeutic efficacy of Desloratadine can be decreased when used in combination with Metoclopramide. The risk or severity of adverse effects can be increased when Canertinib is combined with Desloratadine. The risk or severity of adverse effects can be increased when Desloratadine is combined with Etoperidone. Desloratadine may increase the anticholinergic activities of Tiotropium. The risk or severity of adverse effects can be increased when Alprazolam is combined with Desloratadine. The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Desloratadine. The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Desloratadine. The risk or severity of adverse effects can be increased when Benzocaine is combined with Desloratadine. Desloratadine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.